Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2007

01-05-2007 | Article

Differentiation of Candida albicans from non-albicans yeast directly from blood cultures by Gram stain morphology

Authors: A. Harrington, K. McCourtney, D. Nowowiejski, A. Limaye

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2007

Login to get access

Abstract

Clusters of pseudohyphae are commonly seen on Gram stain of blood cultures from patients with Candida albicans fungemia. Whether this morphologic feature is useful for differentiating C. albicans from other yeasts has not previously been systematically evaluated. Yeast morphology on Gram stain of blood cultures from consecutive patients with fungemia detected by the Bactec automated blood culture system was prospectively assessed and correlated with the final culture-based yeast identification. The distribution of yeast in 60 consecutive patients with fungemia included Candida spp. (C. albicans 43%, Candida glabrata 28%, Candida parapsilosis 8%, Candida krusei 7%, Candida tropicalis 5%, Candida dubliniensis 2%, and Candida lusitaniae 2%), Rhodotorula mucilaginosa 2%, and Cryptococcus neoformans 3%. Upon analysis of the first positive blood culture bottle per patient, the presence of clustered pseudohyphae on Gram stain had a sensitivity, specificity, positive predictive value, and negative predictive value of 85, 97, 96, and 89%, respectively, for C. albicans. The sensitivity and specificity of aerobic vs Myco/F blood culture bottles were 96 and 95% vs 25 and 100%, p < 0.001, respectively. Inter-rater agreement for ten separate observations among five reviewers was 100%. The presence of pseudohyphae clusters by Gram stain of blood cultures is useful in distinguishing C. albicans from non-albicans yeast. Additional studies are necessary to determine the clinical impact of these findings and their validity with other blood culture systems.
Literature
1.
go back to reference Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE (2000) Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30:662–678PubMedCrossRef Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE (2000) Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30:662–678PubMedCrossRef
2.
go back to reference Murri NA (ed) (2006) Drug formulary. Department of Pharmacy Services, University of Washington, Seattle, WA, USA Murri NA (ed) (2006) Drug formulary. Department of Pharmacy Services, University of Washington, Seattle, WA, USA
3.
go back to reference Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ (2002) Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40:852–856PubMedCrossRef Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ (2002) Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40:852–856PubMedCrossRef
4.
go back to reference Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ (2003) Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and E test methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 41:1440–1446PubMedCrossRef Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ (2003) Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and E test methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 41:1440–1446PubMedCrossRef
5.
go back to reference Selvarangan R, Bui U, Limaye AP, Cookson BT (2003) Rapid identification of commonly encountered Candida species directly from blood culture bottles. J Clin Microbiol 41:5660–5664PubMedCrossRef Selvarangan R, Bui U, Limaye AP, Cookson BT (2003) Rapid identification of commonly encountered Candida species directly from blood culture bottles. J Clin Microbiol 41:5660–5664PubMedCrossRef
6.
go back to reference Forrest GN, Mankes K, Jabra-Rizk MA, Weekes E, Johnson JK, Lincalis DP, Venezia RA (2006) Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol 44:3381–3383PubMedCrossRef Forrest GN, Mankes K, Jabra-Rizk MA, Weekes E, Johnson JK, Lincalis DP, Venezia RA (2006) Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol 44:3381–3383PubMedCrossRef
Metadata
Title
Differentiation of Candida albicans from non-albicans yeast directly from blood cultures by Gram stain morphology
Authors
A. Harrington
K. McCourtney
D. Nowowiejski
A. Limaye
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2007
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0291-7

Other articles of this Issue 5/2007

European Journal of Clinical Microbiology & Infectious Diseases 5/2007 Go to the issue

Announcements

Announcements

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine